Clinical trials: Attention Disorder With Hyperactivity (ADHD)
- Condition Attention Disorder With Hyperactivity (ADHD)
- Funder type Industry (pharma, biotech, devices)
Conduct Disorder, Oppositional Defiant Disorder
A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
The purpose of the study is to assess the safety and effectiveness of oral risperidone (an antipsychotic medication) in the treatment of conduct disorder and other disruptive behavior disorders in children ages 5 to 12 with mild…
- Conditions
- Conduct Disorder, Oppositional Defiant Disorder, Disruptive Behavior Disorder
- Trial name
- NCT00250354
- Testing
- Risperidone oral solution
- Volunteers
- 110 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
ADHD, Predominantly Inattentive Type
Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects
The purpose of this study is to evaluate the safety and tolerability of a single administration of Metadoxine Extended Release (MDX) formulation for the treatment of adolescents diagnosed with ADHD that have predominantly…
- Trial name
- NCT02189772
- Testing
- Metadoxine extended release
- Where
- 6 sites in Israel
- Volunteers
- 83 people
- Sponsor
- Alcobra Ltd.
ADHD, ADHD - Combined Type
Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in children (6-12) with ADHD in a laboratory classroom setting.
- Conditions
- ADHD, ADHD - Combined Type, Attention Deficit Hyper Activity, Attention Deficit Hyperactivity Disorder
- Trial name
- NCT05924594
- Testing
- CTx-1301 - Dexmethylphenidate 6.25mg, CTx-1301 - Dexmethylphenidate 12.5mg, CTx-1301 - Dexmethylphenidate 18.75mg
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Cingulate Therapeutics
Attention-Deficit/Hyperactivity Disorder
Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD
The purpose of this study is to assess the efficacy, safety and tolerability of atomoxetine administered once daily in the treatment of adolescents with ADHD after 8 weeks and after 52 weeks
- Trial name
- NCT00191035
- Testing
- Atomoxetine
- Where
- 21 sites in United States
- Volunteers
- 520 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)
The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD
- Trial name
- NCT01654250
- Testing
- NWP09
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- Pfizer
Attention Deficit/Hyperactivity Disorder
Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children
The purpose of this study is to assess the long-term safety of Adhansia XR in children and to characterize the pharmacokinetics (PK) in 4 to 5 year-olds.
- Trial name
- NCT04987762
- Testing
- Adhansia XR
- Where
- 15 sites in United States
- Volunteers
- 103 people
- Sponsor
- Purdue Pharma LP
ADHD, Narcolepsy
Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation (ADAIR)
This is a randomized, double-blind, double-dummy, placebo- and active-controlled 4 period, 4 way crossover study to assess the intranasal abuse potential of manipulated ADAIR formulation in nondependent, recreational stimulant…
- Trial name
- SEAL (NCT04647903)
- Testing
- ADAIR 10 mg IR tablets, d-amphetamine sulfate
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Vallon Pharmaceuticals, Inc.
Attention-Deficit/Hyperactivity Disorder, ADHD
A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The safety and efficacy of multiple dosages of TD-9855, administered once daily, will be evaluated in adult males with ADHD.
- Trial name
- NCT01458340
- Testing
- TD-9855
- Where
- 17 sites in United States
- Volunteers
- 295 people
- Sponsor
- Theravance Biopharma
Attention Deficit Hyperactivity Disorder
"Nuance Hearing" for Attention Deficit Hyperactivity Disorder
The aim of the current study is to examine whether the ability to avoid irrelevant auditory stimuli and focus hearing, enabled by the device developed by "Nuance Hearing", may help students with ADHD in classroom listening…
- Trial name
- ADHD (NCT03902015)
- Testing
- Nuance Phone case
- Volunteers
- 30 people
- Sponsor
- Nuance Hearing
Attention-Deficit/Hyperactivity Disorder
The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
This is a phase 2, randomized, multi-center, double-blind, 3-period and 3-treatment crossover study designed to evaluate the safety and duration of efficacy of SPD465 (50 or 75 mg) compared with placebo and an immediate release…
- Trial name
- NCT00928148
- Testing
- SPD465, Immediate Release Amphetamine Salt
- Volunteers
- 86 people
- Sponsor
- Shire
Attention Deficit Hyperactivity Disorder (ADHD)
A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants
The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT01933880
- Testing
- Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH), No intervention
- Where
- 6 sites in China
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Attention-Deficit/Hyperactivity Disorder
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
The objective of this study is to compare the safety and efficacy of five doses of ABT-089 (2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD and 40 mg BID) to placebo in adults with ADHD.
- Trial name
- NCT00391729
- Testing
- ABT-089
- Where
- 23 sites in United States
- Volunteers
- 221 people
- Sponsor
- Abbott
Attention Deficit Hyperactivity Disorder
CONCERTA Lab School Study
The purpose of this trial is to determine if the study medication, CONCERTA (methylphenidate HCl), is safe and effective in improving academic performance and behavior in children with Attention Deficit Hyperactivity Disorder…
- Trial name
- NCT00799487
- Where
- 3 sites in United States
- Volunteers
- 89 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
Attention Deficit Hyperactivity Disorder
Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)
This is a Phase 2 multicenter, randomized, double-blind trial of MK-8777 (Org 26576, SCH 900777) in adult subjects with Attention-Deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT00610441
- Testing
- MK-8777
- Volunteers
- 67 people
- Sponsor
- Merck Sharp & Dohme LLC
Attention Deficit Disorder With Hyperactivity
Assessment of ARVO Web-based Software for Evaluating Attention-Deficit/Hyperactive Disorder (ADHD) Symptoms in Children
Clinical investigation is aimed to assess the performance and safety of web-based ARVO 2.0, for evaluating possible Attention-Deficit/Hyperactive Disorder (ADHD) symptoms in children.
- Trial name
- NCT05846815
- Testing
- ARVO 2.0 WEB, Conners Continuous Performance Test 3rd Edition™ (CPT 3)
- Where
- Finland
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Peili Vision Ltd.
Attention Deficit Disorder With Hyperactivity
CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults
The purpose of this pilot study is to evaluate the safety, tolerability and potential effectiveness of CONCERTA® (methylphenidate hydrochloride extended-release tablets), a central nervous system (CNS) stimulant for the…
- Trial name
- NCT00246207
- Testing
- CONCERTA (OROS methylphenidate hydrochloride)
- Volunteers
- 32 people
- Sponsor
- Janssen-Ortho Inc., Canada
Attention-Deficit/Hyperactivity Disorder (ADHD)
Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD
To evaluate the efficacy and safety of NRCT-101SR compared to placebo in subjects 13-17 years of age with ADHD
- Trial name
- ADHD (NCT06215144)
- Testing
- NRCT-101SR
- Where
- 13 sites in United States
- Volunteers
- 95 people
- Sponsor
- Neurocentria, Inc.
Attention-Deficit Hyperactivity Disorder (ADHD)
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
A study to evaluate the efficacy and safety of dasotraline in children 6 years of age to 12 years of age with Attention-Deficit Hyperactivity Disorder (ADHD) in a simulated classroom setting.
- Trial name
- NCT02734693
- Testing
- dasotraline 4mg
- Where
- 5 sites in United States
- Volunteers
- 132 people
- Sponsor
- Sumitomo Pharma America, Inc.
ADHD
Efficacy of Neuro+ Attention Training
This study evaluates the efficacy of the Neuro+ Attention Training System (Neuro+) in improving attention skills in children. Half of participants will receive the Neuro+ intervention for 10 weeks, while the other half will…
- Trial name
- NCT02642055
- Testing
- Neuro+ Attention Training, Treatment as Usual
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Neuro+
Attention Deficit Hyperactivity Disorder
Comparison of Atomoxetine Plus Either Comparator or Placebo in Children With ADHD Who Haven't Responded to Stimulant Therapy
The purpose of this study is to evaluate the safety and tolerability of atomoxetine alone versus atomoxetine plus low-dose, sustained-release MPH in children with treatment-resistant ADHD.
- Trial name
- NCT00485550
- Testing
- Atomoxetine Hydrochloride, Methylphenidate Hydrochloride
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Eli Lilly and Company